|
Pfizer Reports Second Phase III Failure in a Week: Torisel, Bevacizumab Combo for Advanced RCC
In the second late-stage failure for Pfizer this week, the company saw disappointing results for its Torisel when combined with Roche’s Avastin as a first-line treatment for advanced renal cell carcinoma (RCC).
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives